Wen-Feng Gong
Overview
Explore the profile of Wen-Feng Gong including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
780
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Qiang N, Gu S, Wang X, Zhang X, Xia S, Zheng J, et al.
Sci One Health
. 2024 Jul;
1:100014.
PMID: 39076599
[This corrects the article DOI: 10.1016/j.soh.2023.100012.].
2.
Qiang N, Gu S, Wang X, Zhang X, Xia S, Zheng J, et al.
Sci One Health
. 2024 Jul;
1:100012.
PMID: 39076597
Background: One Health is an integrated concept of health that aims to optimize the health of humans, animals, plants, and the environment. Identifying research gaps and specific expertise areas is...
3.
Zhang X, Lederman Z, Han L, Schurer J, Xiao L, Zhang Z, et al.
Infect Dis Poverty
. 2024 Apr;
13(1):28.
PMID: 38610035
Background: Despite the increasing focus on strengthening One Health capacity building on global level, challenges remain in devising and implementing real-world interventions particularly in the Asia-Pacific region. Recognizing these gaps,...
4.
Li J, Su T, Gong W, Zhong J, Yan L, Zhang J, et al.
Hepatol Int
. 2022 Aug;
16(5):1179-1187.
PMID: 36001228
Purpose: Stereotactic body radiotherapy (SBRT) may have significant immunomodulatory effects that enhance tumor response to immune checkpoint inhibitors. This phase 2 clinical trial was conducted to evaluate the safety and...
5.
Qi L, Ma L, Wu F, Chen Y, Xu J, Peng Y, et al.
Liver Int
. 2022 Jul;
42(10):2283-2298.
PMID: 35810457
Background & Aims: The multiplicity of hepatocellular carcinoma (HCC) recurrence patterns is the most important determinant of patients' postsurgical survival. A systematic HCC recurrence classification is needed to help prevent...
6.
Chen K, Wei W, Liu L, Deng Z, Li L, Liang X, et al.
Cancer Immunol Immunother
. 2021 Sep;
71(5):1063-1074.
PMID: 34559308
Background: Lenvatinib is regarded as the first-line therapy for patients with unresectable hepatocellular carcinoma (HCC). This study assessed the efficacy and safety of lenvatinib with or without immune checkpoint inhibitors...
7.
Huo R, Liu H, Deng Z, Liang X, Gong W, Qi L, et al.
Front Oncol
. 2021 Jan;
10:596691.
PMID: 33505912
Background: The relationship between serum prealbumin and the risk of all-cause mortality after hepatectomy in patients with hepatocellular carcinoma (HCC) needs to be evaluated. Methods: We conducted a retrospective study....
8.
Qi L, Ma L, Wu F, Chen Y, Xing W, Jiang Z, et al.
Hepatol Int
. 2021 Jan;
15(1):114-126.
PMID: 33495903
Background: Portal vein tumor thrombus (PVTT) and microvascular invasion (MVI) are types of intrahepatic vascular metastasis of hepatocellular carcinoma (HCC) and are highly correlated with poor prognosis. However, the underlying...
9.
Deng Z, Liu H, Gong W, Xiang B, Zhong J
Aliment Pharmacol Ther
. 2020 Nov;
52(11-12):1767-1768.
PMID: 33205874
No abstract available.
10.
Li C, Li Z, Ma L, Li L, Zhong J, Xiang B, et al.
Expert Rev Gastroenterol Hepatol
. 2020 Jun;
14(8):749-756.
PMID: 32552297
Objective: To investigate the effect of perioperative antiviral therapy on the prognosis of hepatitis B virus (HBV) DNA-negative patients with HBV-related hepatocellular carcinoma (HCC). Methods: The clinical data of 140...